Using semaglutide to treat psoriasis in obese patients
Official title: Effect of Semaglutide in Patients With Psoriasis and Obesity
Run by The University of Hong Kong · NCT06937060 · Data updated 2026-11-12
This study is testing if the weight loss drug semaglutide can help improve psoriasis symptoms in adults who are both obese and have psoriasis.
Quick facts
| Phase | Phase 3 |
|---|---|
| Study type | Interventional |
| Ages | 18 Years to 75 Years |
| Sex | All |
| Enrollment | 14 (estimated) |
| Sponsor | The University of Hong Kong Academic / other |
| Locations | 1 site (Hong Kong) |
| Status | Recruiting |
| Started | March 20, 2025 |
| Main results expected | July 31, 2026 |
| Study ends | January 31, 2027 |
| Registry record updated | May 13, 2025 |
| Trial ID | NCT06937060 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates are Chinese adults aged 18 to 75 with moderate to severe psoriasis and obesity or overweight.
✕Probably not a fit
Patients with type 1 diabetes, a history of pancreatitis, or contraindications to GLP1 RA will not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This clinical trial investigates the effects of semaglutide, a glucagon-like peptide-1 receptor agonist, on patients suffering from psoriasis and obesity. The study aims to determine whether weight loss achieved through semaglutide can lead to improvements in psoriasis severity and overall disease management. Eligible participants include adults aged 18 to 75 with a clinical diagnosis of psoriasis and a body mass index indicating obesity or overweight. The trial will monitor the efficacy of semaglutide in reducing psoriasis symptoms while addressing weight-related health issues.
Why it matters
Potential benefit: If successful, this treatment could significantly improve psoriasis symptoms and overall health in obese patients.
How similar studies have gone: Previous studies have shown the efficacy of older GLP1 RAs in improving psoriatic disease activity, but trials specifically on semaglutide for this purpose are novel.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * a clinical diagnosed Psoriatic disease of at least 6 months before signing of informed consent. * Women who are sexually active and not postmenopausal, agreement to remain abstinent or use 2 effective methods of contraception * \>18 years of age, up to 75 years of age * Adult with an initial body mass index (BMI) of 30 kg/m2 or greater (obesity) or 27 kg/m2 or greater (overweight) in the presence of at least one weight-related comorbid condition (e.g., hypertension, type 2 diabetes mellitus, or dyslipidemia) * Moderate to severe psoriasis (PASI score 5-10= moderate, \>10 = severe) * Chinese ethnicity * On stable dose of standard treatment * Ability to comply with stud Exclusion Criteria: * Patients who refuse to give consent * Contraindication to use of GLP1 RA * History of pancreatitis * History of MEN / MTC * Known hypersensitivity to semaglutide or excipients in semaglutide * Type 1 diabetes * Gallbladder disease * Active malignancy or History of malignancy within 5 years * Active chronic or acute infection requiring treatment with systemic antibiotics, antiviral, antiparasitic, antiprotozoal, or antifungals within 4 weeks before baseline visit * Pregnancy or breastfeeding, subjects should inform their healthcare provider of a known or suspected pregnancy * History of allergic reaction assessed as related to investigational product by the investigator * Major psychiatric illness * Treatment with live/ attenuated vaccine within the last 28 days prior to randomisation * History of alcohol or substance abuse within 6 months prior to initial screening * Patients with a history of suicidal attempts or active suicidal ideation
Where it's running
-
The University of Hong Kong, Department of Medicine
Hong Kong, Hong Kong Recruiting
Study contacts
- Principal investigator: Man Ho Martin Chung — The University of Hong Kong
- Study coordinator: Man Ho Martin Chung
- Email: drcmhm@hku.hk
- Phone: 22553111
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Retinal Vessel Density and Foveal Avascular Zone Size in Psoriatic Arthritis
This study tests whether retinal blood vessel density and the size of the foveal avascular zone differ between people with psoriatic arthritis, people with psoriasis, and healthy individuals using non-invasive eye imaging.
-
IBI3046 in Overweight or Obesity
This study tests how safe and tolerable IBI3046 is in adults with overweight or obesity in China.
-
Is XJH05 Ointment Effective for Plaque Psoriasis?
This study tests whether the XJH05 ointment can help people with plaque psoriasis compare to a calcipotriol ointment.
-
HL40626S tablets in healthy adults: a first-in-human dose study
This Phase 1 study tests HL40626S tablets in healthy adults to see if it is safe, tolerated, and how it behaves in the body after single and 14-day multiple doses.
-
Global psoriasis care patterns and outcomes (observational)
This study tests how psoriasis is managed across different health systems by following patients over time to see care access, treatments, disease severity, and quality of life.
-
S-4321 in adults with autoimmune or immune-mediated diseases
This study tests S-4321 in adults with autoimmune conditions to see if it is safe and tolerable and to gather early data on how the drug behaves in the body and its initial effects on disease markers.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.